Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.73 – $8.58
51% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $375.4M | $446.4M | $500.9M | $618.0M | $751.4M | $781.4M | $797.0M | $788.1M |
| Cost of revenue | $263.4M | $313.5M | $375.2M | $466.5M | $577.4M | $606.4M | $682.1M | $722.9M |
| Gross profit | $112.0M | $132.9M | $125.7M | $151.5M | $174.1M | $175.1M | $114.9M | $65.2M |
| Gross margin | 29.8% | 29.8% | 25.1% | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| R&D | $35.6M | $58.4M | $63.9M | $72.2M | $76.6M | $73.9M | $50.9M | $77.4M |
| Operating income | $77.5M | $62.6M | $48.5M | $41.0M | $20.9M | −$47.5M | −$142.5M | −$140.8M |
| EBITDA | $105.9M | $112.9M | $90.4M | $313.8M | −$59.1M | $24.1M | −$80.7M | −$41.4M |
| Net income | $84.2M | $38.2M | $6.3M | $215.5M | −$175.7M | −$83.9M | −$196.1M | −$103.5M |
| Net margin | 22.4% | 8.5% | 1.3% | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (diluted) | 0.57 | 0.25 | 0.04 | 1.29 | -0.99 | -0.47 | -1.11 | -0.58 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $728M | $-0.70 | $-0.81–$-0.63 | 1 |
| 2027 | $799M | $-0.11 | $-0.13–$-0.10 | 1 |
| 2028 | $894M | $0.24 | $0.22–$0.28 | 1 |
| 2029 | $951M | $0.46 | $0.42–$0.53 | 1 |
Forward consensus · source: Financial Modeling Prep
EVOTEC SE
No one on the platform currently holds EVOTF.
No tracked institution reports a position in EVOTF as of their last filing.
No one on the platform has traded EVOTF yet.
| +0.00% |
| $818M |
| — |
| KSPHFKissei Pharmaceutical Co., Ltd. | $25.77 | +0.00% | $1.1B | — |
| LJUIFSSY Group Limited | $0.40 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.5× sales vs its 3.6× historical median P/S.
Fair value ≈ $16.03 · price $6.69 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.